Navigation Links
Alfacell Provides Shareholder Update
Date:6/19/2009

o conduct a clinical trial in non small cell lung cancer (NSCLC) in patients who have become resistant to platinum therapy. Dr. David Sidransky (Alfacell Chairman of the Board) is spearheading this effort and is in the process of finalizing a special protocol assessment (SPA) which will be presented to the FDA. The patients will be evaluated radiologically for tumor response and will also be evaluated for the time to tumor progression, survival, and side effects of treatment.

Today, other important scientific developments are underway. We are investigating ways to generate revenue from our compounds outside of the clinical and regulatory arena. One such experiment we are looking into is whether Onconase can be used as routine tool to detect the gene silencing via RNA interference (RNAi) mechanism. Currently, there are thousands of researchers interested in finding the answer about the RNAi-mediated gene regulation using their gene of interest. Should we be able to get a positive result, researches from all over the world could be potential buyers of Onconase. We anticipate results shortly.

Other studies will be conducted in order to elucidate if Onconase is able to down regulate the protein produced by the MDR1 gene. There is ample evidence this may be the case, and if so, as previously mentioned, Onconase would be a strong candidate to be used as an adjunct to other chemo therapy regimes.

Of course, our ability to continue with these efforts will depend on our ability to obtain additional financing in the near-term. Talks have been ongoing with potential private investors regarding recapitalizing the company. We cannot assure you, however, that we will be able to secure the necessary financing to maintain the company's operations and pursue these worthwhile projects. It is my sincere hope investors and shareholders alike will see the value in our compounds and continue supporting the company. As I stated earlie
'/>"/>

SOURCE Alfacell Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alfacell Provides ONCONASE(R) NDA Submission Update
2. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
3. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
4. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
5. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
6. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
7. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 11, 2014  Major advances ... of cancer are being highlighted in a three-day ... from 10-12 July, 2014.  Renowned national and ... share best practices and exchange knowledge on modern ... accurate and efficient. The Summit ...
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... fourth quarter and fiscal year ended June 30, 2014 results ... Exchange market close. A press release with ResMed,s results will ... company will host a webcast to discuss operating results and ... begin at 1:30 p.m. US Pacific Time and the live ...
(Date:7/10/2014)...  Decision Resources Group finds that while more ... are willing to prescribe Durata,s Dalvance (dalbavancin) and ... OPAT, approximately two-thirds of the respondents reported a ... inpatients. However, our findings indicate that nearly two-thirds ... OPAT following hospital discharge, and most are discharged ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Nov. 4, 2010 Valeant Pharmaceuticals International, Inc. (NYSE: ... the Company,s Board of Directors (the "Board") has declared ... (the "Special Dividend") that shareholders of record as of ... "Record Date") will be entitled to receive on December ...
... Cardiogenesis Corporation (OTCQB: CGCP), a leading developer of surgical ... disease, today reported financial results for its third quarter ... Revenue for the third quarter of 2010 was ... revenue of $2,134,000.  Gross margin was 84% for the ...
Cached Medicine Technology:Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan 2Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan 3Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan 4Cardiogenesis Reports Third Quarter 2010 Results 2Cardiogenesis Reports Third Quarter 2010 Results 3Cardiogenesis Reports Third Quarter 2010 Results 4Cardiogenesis Reports Third Quarter 2010 Results 5Cardiogenesis Reports Third Quarter 2010 Results 6
(Date:7/12/2014)... (PRWEB) July 12, 2014 “Critical ... - New and Late-Stage Four-Factor PCCs and Recombinant ... of the critical care market in the US, ... The report provides an estimation of market size ... It covers critical care indications that are being ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Dubai is ... basketball legend is heading to the UAE. The ... champion will be in the UAE from 28-31 October ... in support of diabetes awareness. The event is being ... marketing and event management company based in Dubai. The ...
(Date:7/12/2014)... Seattle, Wa (PRWEB) July 12, 2014 ... by Doctors Sen and Samantha Pearson, a couple boasting ... chose to launch Restore My Vision Today as a ... that many ophthalmologists have become in their respective ... makes readers privy to a “secret” trove of pertinent ...
(Date:7/12/2014)... 2014 Ladies, it doesn't matter what your ... who are looking for an affordable gown can visit ... dresses) to get their dream items. Recently, the company has ... gowns . Along with that, it is also providing great ... special offer; the deadline of this promotion is July 29, ...
(Date:7/11/2014)... 2014 According to new report ... is expected to register a CAGR of 2.28% ... 71 market data tables and 76 figures spread ... Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early buyers will ... , The report provides market analysis of ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4
... Income Protection, Offers Tips for Obtaining Coverage , ARLINGTON, Va., ... survey show the historic recession has left many Americans with ... they are more vulnerable to serious financial hardship in the ... work. According to the nonprofit LIFE Foundation, more than a ...
... and Afghanistan ... To help ease the transition and readjustment challenges facing Iraq ... of America (IAVA) joined the Ad Council today to launch a ... Support Campaign. Launched on Veterans Day 2008, the first series of ...
... distinguished professor at Kansas State University,s Division of Biology, ... from The National Eye Institute of the National Institutes ... renewal will make Conrad,s grant the longest continuously funded ... years," said Jim Guikema, K-State associate vice president for ...
... of a statin in time of crisis improved long-term ... -- Giving patients a cholesterol-busting statin drug during a ... of longer-term problems, Czech researchers say. , The one-year ... than halved for people suffering life-threatening episodes of acute ...
... Data Presented at American Heart Association ATVB Conference Shows ... Lesions in Treated PatientsWASHINGTON and SAN FRANCISCO, May 1 ... today announced the results of a sub-study of patients ... who received serial 64 slice multidetector computed tomography (MDCT) ...
... Wash., May 1 SCOLR Pharma, Inc. (NYSE Amex: ... ended March 31, 2009. The Company will host a ... (Eastern Daylight Time).Bruce S. Morra, SCOLR Pharma,s President and CEO, ... our two lead product candidates, ibuprofen and pseudoephedrine, and the ...
Cached Medicine News:Health News:Hit Hard by the Economy, Americans Risk Knockout Without Disability Insurance 2Health News:Hit Hard by the Economy, Americans Risk Knockout Without Disability Insurance 3Health News:Hit Hard by the Economy, Americans Risk Knockout Without Disability Insurance 4Health News:Video: IAVA and Ad Council Build on Success of Groundbreaking Veterans Campaign with New Friends and Family Element 2Health News:Video: IAVA and Ad Council Build on Success of Groundbreaking Veterans Campaign with New Friends and Family Element 3Health News:Video: IAVA and Ad Council Build on Success of Groundbreaking Veterans Campaign with New Friends and Family Element 4Health News:K-State professor awarded $1.48 million to study LASIK complictions 2Health News:K-State professor awarded $1.48 million to study LASIK complictions 3Health News:Cholesterol Drugs May Help in Cardiac Emergency 2Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 2Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 3Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 4Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 5Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 2Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 3Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 4Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 5Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 6Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 7
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
BD Vacutainer® Specialty Tubes - Other - Glass...
BD Vacutainer® Specialty Tubes - Other - Plastic...
BD Vacutainer® Specialty Tubes - Lead Testing...
Medicine Products: